- Home
- RGC vs ACHV Comparison
RGC vs ACHV Comparison
Compare RGC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- ACHV
- Stock Information
- Founded
- RGC 2014
- ACHV N/A
- Country
- RGC Hong Kong
- ACHV Canada
- Employees
- RGC N/A
- ACHV N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RGC Health Care
- ACHV Health Care
- Exchange
- RGC Nasdaq
- ACHV Nasdaq
- Market Cap
- RGC 105.3M
- ACHV 126.9M
- IPO Year
- RGC 2021
- ACHV N/A
- Fundamental
- Price
- RGC $4.86
- ACHV $3.15
- Analyst Decision
- RGC
- ACHV Strong Buy
- Analyst Count
- RGC 0
- ACHV 5
- Target Price
- RGC N/A
- ACHV $14.80
- AVG Volume (30 Days)
- RGC 8.8K
- ACHV 260.4K
- Earning Date
- RGC 10-25-2024
- ACHV 11-07-2024
- Dividend Yield
- RGC N/A
- ACHV N/A
- EPS Growth
- RGC N/A
- ACHV N/A
- EPS
- RGC N/A
- ACHV N/A
- Revenue
- RGC N/A
- ACHV N/A
- Revenue This Year
- RGC N/A
- ACHV N/A
- Revenue Next Year
- RGC N/A
- ACHV N/A
- P/E Ratio
- RGC N/A
- ACHV N/A
- Revenue Growth
- RGC N/A
- ACHV N/A
- 52 Week Low
- RGC $3.03
- ACHV $3.12
- 52 Week High
- RGC $32.44
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- RGC 44.96
- ACHV 26.85
- Support Level
- RGC $4.75
- ACHV $3.50
- Resistance Level
- RGC $5.21
- ACHV $3.86
- Average True Range (ATR)
- RGC 0.30
- ACHV 0.20
- MACD
- RGC 0.04
- ACHV -0.03
- Stochastic Oscillator
- RGC 23.87
- ACHV 4.05
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.